Degli Esposti Luca, Veronesi Chiara, Ancona Domenica Daniela, Andretta Margherita, Bartolini Fausto, Drei Alberto, Lupi Alessandro, Palcic Stefano, Re Davide, Rizzi Francesca Vittoria, Giacomini Elisa, Perrone Valentina
CliCon S.r.l. Health, Economics & Outcomes Research, Bologna, Italy.
Dipartimento Farmaceutico, ASL BAT, Trani, Italy.
Clinicoecon Outcomes Res. 2022 Mar 10;14:139-147. doi: 10.2147/CEOR.S345852. eCollection 2022.
This real-world study investigates the direct healthcare costs from the perspective of the Italian Healthcare National Service of experienced statin users according to their level of adherence to therapy and to their cardiovascular (CV) profile in Italian settings of outpatients clinical practice.
A retrospective observational analysis was performed based on administrative databases covering approximately 6 million health-assisted individuals. Adult patients with statins prescription between January 2014 and December 2016 were screened, and first prescription within this period was the index date. Follow-up lasted 1 year after index date. Only patients receiving statins prior index date (experienced statin users) were included and distributed in clusters based on their CV profile. Adherence was calculated during follow-up as proportion of days covered (PDC) and classified in low adherence (PDC<40%), partial adherence (PDC=40-79%) and adherence (PDC≥80%). Mean direct healthcare costs of drugs, hospitalizations, and outpatient services were evaluated during follow-up.
A total of 436,623 experienced statin users were included and distributed as follows: 5.5% in the previous CV events, 22.6% in diabetes, 55.7% in CV treatments and 16.2% in the no comorbidity cluster. Total mean annual cost/patient decreased from low adherent to adherent patients from €4826 to €3497 in previous CV events, from €2815 to €2360 in diabetes cluster, from €2077 to €1863 for patients with CV treatments. Same trend was reported for the cost item related to hospitalizations, which was the major determinant of the total costs. In previous CV event cluster, adherence was associated to a saving of €879 on total costs.
The study highlighted a decrease in overall mean costs as adherence levels increase, particularly for patients with previous CV events, showing how improving adherence could be associated to cost savings and suggesting suited strategy based on CV profile should be undertaken for adherence optimization.
本项真实世界研究从意大利国家医疗服务体系的角度,调查了在意大利门诊临床实践环境中,经验丰富的他汀类药物使用者根据其治疗依从性水平和心血管(CV)状况产生的直接医疗费用。
基于涵盖约600万受医保资助个体的行政数据库进行回顾性观察分析。筛选出2014年1月至2016年12月期间有他汀类药物处方的成年患者,将该期间的首次处方日期作为索引日期。索引日期后随访1年。仅纳入在索引日期前接受他汀类药物治疗的患者(经验丰富的他汀类药物使用者),并根据其CV状况进行分组。随访期间,依从性按覆盖天数比例(PDC)计算,并分为低依从性(PDC<40%)、部分依从性(PDC = 40 - 79%)和依从性(PDC≥80%)。随访期间评估了药物、住院和门诊服务的平均直接医疗费用。
共纳入436,623名经验丰富的他汀类药物使用者,分布如下:既往有CV事件的患者占5.5%,糖尿病患者占22.6%,接受CV治疗的患者占55.7%,无合并症组患者占16.2%。在既往有CV事件的患者中,每位患者的年均总费用从低依从性患者的4826欧元降至依从性患者的3497欧元;在糖尿病组中,从2815欧元降至2360欧元;在接受CV治疗的患者中,从2077欧元降至1863欧元。住院相关费用项目也呈现相同趋势,住院费用是总费用的主要决定因素。在既往有CV事件组中,依从性与总费用节省879欧元相关。
该研究强调随着依从性水平的提高,总体平均费用会降低,尤其是既往有CV事件的患者,这表明提高依从性可能与成本节约相关,并建议应根据CV状况采取合适的策略来优化依从性。